Anchiano Therapeutics, a late-stage biotech developing therapies for early-stage bladder cancer, raised $31 million by offering 2.7 million ADSs at $11.50, below the expected price of $14.55.
At $11.50, Anchiano Therapeutics would command a market cap of $78 million. The company previously filed to raise $35 million by offering 2.4 million ADSs at $14.55.
Anchiano Therapeutics plans to list on the Nasdaq under the symbol ANCN. Oppenheimer & Co. acted as a lead manager on the deal.
